Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Factors Affecting Erythropoiesis

Factors Affecting Erythropoiesis

The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...

Erythropoiesis

Erythropoiesis

Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...

Erythropoiesis

Erythropoiesis

Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...

Role of Hematopoietic Growth Factors

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Qualified prediction system for allograft failure in real world settings: extended validation study.

BMJ medicine·2026

Same author

Long-Term Outcome of Kidney Transplant Patients from Rural Farming Areas with Balkan Nephropathy-A Single-Centre Report.

Journal of clinical medicine·2026

Same author

Post-Transplant Sepsis After Liver Transplantation: Clinical Characteristics and Therapeutic Challenges.

Journal of clinical medicine·2026

Same author

Uremic Pruritus in Hemodialysis: Mechanisms, Burden, and Emerging Therapies.

Journal of clinical medicine·2026

Same author

Exploring Perspectives on Kidney Donation: Medical and Non-Medical Students in Croatia.

Journal of clinical medicine·2026

Same author

Oral Nutritional Supplement Adherence and Nutritional Outcomes in Hemodialysis Patients-A Prospective Study.

Journal of clinical medicine·2025

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

Published on: January 10, 2025

[Erythropoesis-stimulating agents: past, present and future].

Petar Kes¹, Nikolina Basić-Jukić

¹Zavod za dijalizu, Klinicki bolnicki centar Zagreb, Zagreb. kespetar@net.hr

Acta Medica Croatica : Casopis Hravatske Akademije Medicinskih Znanosti

|March 18, 2010

Summary

Erythropoiesis-stimulating agents (ESAs) treat renal anemia in chronic kidney disease (CKD) patients. Beyond correcting anemia, ESAs offer organ protection and may improve cardiac and renal function.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis

Published on: September 9, 2014

Related Experiment Videos

Last Updated: Jun 15, 2026

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

Published on: January 10, 2025

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis

Mouse Fetal Liver Culture System to Dissect Target Gene Functions at the Early and Late Stages of Terminal Erythropoiesis

Published on: September 9, 2014

Area of Science:

Nephrology
Hematology
Cardiology

Context:

Renal anemia is a common complication of chronic kidney disease (CKD).
Erythropoietin (EPO) deficiency is the primary cause of renal anemia.
Anemia in CKD is linked to adverse cardiovascular outcomes and a worsening cycle with renal and heart failure (anemia-renalcardio syndrome).

Purpose:

To explore the multifaceted benefits of erythropoiesis-stimulating agents (ESAs) in treating renal anemia.
To highlight the organ-protective effects of ESAs beyond simple anemia correction.

Summary:

Erythropoiesis-stimulating agents (ESAs) effectively treat renal anemia in CKD patients.
ESAs provide organ protection through both hematopoiesis-dependent and -independent mechanisms.
EPO exhibits pleiotropic effects on the kidney, central nervous system, and cardiovascular system.

Impact:

Early recognition and ESA treatment of renal anemia can benefit many CKD patients.
ESA administration has shown potential in reducing brain injury and spinal cord injury.
ESA treatment can improve cardiac function in heart failure patients and potentially enhance renal function in select individuals.